Bionyra Pharma launched from stealth with $165 million in funding and a portfolio of three extended-half-life biologics targeting TL1A signaling, alone and in combination. The company was formed by Sofinnova Partners and led by Frédéric Marrache, previously head of immunology R&D at Sanofi. Bionyra’s pipeline includes BYN-002, a monoclonal antibody against TL1A in Phase 1 studies, and BYN-003, a bispecific antibody combining TL1A with an IL-23-related target. The third asset, BYN-001, is an anti-IL-25 monoclonal antibody planned for atopic dermatitis and other inflammatory indications, with the program designed around less frequent dosing. The launch positions Bionyra to compete in a crowded immunology market where investors have been funding differentiation around longer dosing intervals, improved response rates, and combination regimens that can reduce safety limitations tied to other mechanisms. The company said two of the programs are already in Phase 1, aiming to move clinical assets toward combination studies. The most immediate industry takeaway is how quickly TL1A biology is being turned into clinical programs with capital sufficient to run multiple early trials and explore combination strategies for conditions spanning IBD and atopic dermatitis.